Daniel A Luedtke

Statistics

Publications

Citations

360

H-Index

Active since

2017

Affiliations

The Barbara Ann Karmanos Cancer Institute(Current)

Wayne State University

Children's Hospital of Michigan

First Hospital of Jilin University

Jilin University

Daniel A Luedtke is an author at The Barbara Ann Karmanos Cancer Institute specializing in pharmacology, chemotherapy, and chemotherapy in hematologic malignancies.

ORCID

Publications per year

2017–2020

Publications

Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells

Daniel A Luedtke, Xiaojia Niu, Yihang Pan et al. · Signal Transduction and Targeted Therapy · 2017 · 126 citations · Full text

Medicine, Oncology, Pharmacology +17

Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia

Daniel A Luedtke, Yongwei Su, Jun Ma et al. · Signal Transduction and Targeted Therapy · 2020 · 67 citations · Full text

Medicine, Oncology, Pharmacology +15

Inhibition of <scp>XPO</scp>1 enhances cell death induced by <scp>ABT</scp>‐199 in acute myeloid leukaemia via Mcl‐1

Daniel A Luedtke, Yongwei Su, Shuang Liu et al. · Journal of Cellular and Molecular Medicine · 2018 · 63 citations · Full text

Medicine, Oncology, Pharmacology +17

Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells

Jun Ma, Xinyu Li, Yongwei Su et al. · Scientific Reports · 2017 · 58 citations · Full text

Life Sciences, Oncology, Pharmacology +17

H<sub>2</sub>O<sub>2</sub>/Peroxynitrite-Activated Hydroxamic Acid HDAC Inhibitor Prodrugs Show Antileukemic Activities against AML Cells

Yi Liao, Liping Xu, Siyu Ou et al. · ACS Medicinal Chemistry Letters · 2018 · 46 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

1–5 of 5